Data-Mining Methods as Useful Tools for Predicting Individual Drug Response: Application to CYP2D6 Data
- 1 November 2006
- journal article
- Published by S. Karger AG in Human Heredity
- Vol. 62 (3) , 119-134
- https://doi.org/10.1159/000096416
Abstract
Selecting a maximally informative subset of polymorphisms to predict a clinical outcome, such as drug response, requires appropriate search methods due to the increased dimensionality associated with looking at multiple genotypes. In this study, we investigated the ability of several pattern recognition methods to identify the most informative markers in the CYP2D6 gene for the prediction of CYP2D6 metabolizer status. Four data-mining tools were explored: decision trees, random forests, artificial neural networks, and the multifactor dimensionality reduction (MDR) method. Marker selection was performed separately in eight population samples of different ethnic origin to evaluate to what extent the most informative markers differ across ethnic groups. Our results show that the number of polymorphisms required to predict CYP2D6 metabolic phenotype with a high accuracy can be dramatically reduced owing to the strong haplotype block structure observed at CYP2D6. MDR and neural networks provided nearly identical results and performed the best. Data-mining methods, such as MDR and neural networks, appear as promising tools to improve the efficiency of genotyping tests in pharmacogenetics with the ultimate goal of pre-screening patients for individual therapy selection with minimum genotyping effort.Keywords
This publication has 69 references indexed in Scilit:
- Combinatorial PharmacogeneticsNature Reviews Drug Discovery, 2005
- Optimal Selection of SNP Markers for Disease Association StudiesHuman Heredity, 2004
- Mathematical multi-locus approaches to localizing complex human trait genesNature Reviews Genetics, 2003
- Analysis of multilocus models of associationGenetic Epidemiology, 2003
- Power of multifactor dimensionality reduction for detecting gene‐gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneityGenetic Epidemiology, 2003
- Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activityThe Pharmacogenomics Journal, 2002
- Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O‐demethylation in different CYP2D6 genotypesBritish Journal of Clinical Pharmacology, 2000
- Decreased capacity for debrisoquine metabolism among black TanzaniansPharmacogenetics, 1999
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 1993